Algorithm for the diagnosis and treatment of primary placental dysfunction in pregnant women of risk groups




placental dysfunction, diagnosis, treatment


Research objective: to evaluate the effectiveness of diagnosis and complex therapy of placental dysfunction (PD) in early stages of gestation.
Materials and methods. We examined 110 pregnant women with risk for the primary PD. Exclusion criteria were multiple pregnancies, anomalies of fetal development and internal genital organs of the mother, pregnancy resulting from assisted reproductive technologies.
The diagnosis of PD was established in 56 women (group I) based on the assessing the state of extraembryonic structures and blood flow in the spiral and uterine arteries at 12–13 weeks of gestation. The rest of the patients (54 women) entered the control group without PD (group II).
Results. All pregnant women with verified PD at 12–13 weeks were prescribed complex drug treatment, which included micronized progesterone, venotonic Normoven, Magnicum, and Artihol. As a result of treatment, already at 22–24 weeks of gestation, the average value of blood flow (resistance index) in the uterine and spiral arteries did not differ significantly in the groups. There was no significant difference in fetometry and placentometry indices at 35–36 weeks of gestation. Complications of the gestational period in patients in the study groups were also almost the same.
Conclusions. History of hormonal disorders and miscarriage, clinical signs of miscarriage in early gestation, abnormal embryo placement, extragenital pathology, and genital tract infections are risk factors for PD. Determination of the state of extraembryonic structures at 7–8 weeks of pregnancy (ovum volume, blood flow in the corpus luteum) and at 12–13 weeks (chorion volume, vascularization index, blood flow in the spiral and uterine arteries) can serve as a verification criterion for the PD development. Complex drug therapy, which began from the early stages of gestation (micronized progesterone, Normoven, Magnicum, Artihol) has established itself as an effective method of treating primary PD in pregnant of risk groups.

Author Biography

O.V. Kravchenko, Higher State Educational Institution of Ukraine “Bukovinian State Medical University”, Chernivtsi

MD, professor, head of Obstetrics, Gynecology and Perinatology Department


  1. Borzenko, I.B. “Prognosis and early diagnosis of placental dysfunction (literature review).” Ukrainian Journal of Medicine, Biology and Sports 5.2.24 (2020): 7–17.
  2. Veres, I.A. “Application of cytoflavin in the treatment of pregnant women with placental insufficiency.” Modern medicine: current issues: Sat. Art. by mater. L international. scientific-practical conf 44.12 (2015).
  3. Herman, L.V. Optimization of diagnosis and treatment of placental dysfunction in pregnant women with miscarriage: Thesis for the candidate degree of medical sciences. Chernivtsi (2015): 153 p.
  4. Dikke, G.B. “The role of magnesium in physiological pregnancy: controversies and evidence.” Med Advice 19 (2016): 96–102.
  5. Zhabchenko, I.A., Tsypkun, A.G., Zhitskiy, A.M., et al. “Modern approaches to the diagnosis and treatment of placental dysfunction.” Taurian Medical and Biological Bulletin (2011): 81–8.
  6. Zvyagintseva, T.D., Shargorod, I.I. “Biliary dysfunctions and methods of modern therapy.” Family medicine 72.4 (2017): 129–32.
  7. Lazareva, G.A., Khuraseva, А.B., Klycheva, O.I. “Modern view on the problem of fetoplacental insufficiency.” Scientific Bulletin. Medicine series. Pharmacy 27.189.18 (2014): 5–10.
  8. Mamedalieva, N.M., Raeva, P.M. “Prevention and treatment of varicose veins and its complications in obstetrics.” Women's Health 80.4 (2013): 75–6.
  9. Medved, V.I. “Venous complications: classifications of major complications. Variants of treatment of varicose complications in pregnant women.” MedProsvita. Available from: [].
  10. Gromova, O.A., Torshin, I.Y., Pronin, A.V., et al. “Meta-analysis of the effectiveness and safety of organic magnesium salts in obstetric practice.” Obstetrics and gynecol 10 (2014): 33–40.
  11. Dzhobava, S.Z., Ilyina, I.Y., Chikisheva, A.A., et al. “New approaches to the correction of thrombophilic disorders of hemostasis during pregnancy: the role of magnesium: the effectiveness of therapy and combined effects.” Gynecologist 14 (2012): 55–60.
  12. Korchynska, O.O., Chernyak, M.M., et al. “Prevention and treatment of placental dysfunction in modern obstetrics.” Ukraine. The health of the nation 40.4 (2016): 171–5.
  13. Nikolaeva, L.B., Makatsaria, A.D., Shestopalova, E.A., Prosvetova, A.A. “The role of magnesium preparations in improving the outcomes of the first pregnancy.” Obstetrics and gynecol 11 (2013): 79–82.
  14. Tezikov, Y.V. “Complex treatment of placental insufficiency with inclusion of diosmin angioprotector.” Women's Health 106.10 (2015): 94–7.
  15. Fofanova, I.Y. “Magnesium deficiency and its connection with obstetric pathology.” Remedium (2014). Available from: [http://].
  16. Chebotareva, Y.Y., Petrov, Y.A., Baikulova, T.Y. “Prevention and correction of placental insufficiency in primiparous women.” Electronic scientific journal. Modern problems of science and education 5 (2015). Available from: [].
  17. Yasnopolskaya, N.V. Efficacy of oral venotonics in chronic venous insufficiency: results of a 2016 Cochrane meta-analysis. M.: GEOTAR-Media (2020). Available from: [].
  18. Yamada, K., Ishii, Y., Takeda, T., et al. “Effect of Cynaropicrin on 2, 3, 4, 7, 8-Pentachlorodibenzofuran- induced Wasting Syndrome and Oxidative Stress.” Fukuoka Igaku Zasshi 106.5 (2015): 169–75.
  19. Gaccioli, F., Lager, S. “Placental nutrient transport and intrauterine growth restriction.” Front Physiol 7 (2016): 40. DOI: 10.3389/fphys.2016.00040
  20. Magielse, J., Verlaet, A., Breynaert, A., et al. “Investigation of the in vivo antioxidative activity of Cynara scolymus (artichoke) leaf extract in the streptozotocin-induced diabetic rat.” Mol Nutr Food Res 58.1 (2014): 211–5. DOI: 10.1002/mnfr.201300282
  21. Longtine, M.S., Nelson, M. “Placental Dysfunction and Fetal Programming: The Importance of Placental Size, Shape, Histopathology, and Molecular Composition.” Semin Reprod Med 29.3 (2011): 187–96. DOI: 10.1055/s-0031-1275515
  22. Ulu, İ., Çekmez, Y., Yıldırım Köpük, Ş., et al. “Maternal serum thrombospondin-1 is significantly altered in cases with established preeclampsia.” The Journal of Maternal-Fetal & Neonatal Medicine 32.15 (2019): 2543–6. DOI: 10.1080/14767058.2018.1441279
  23. Miller, S.L., Huppi, P.S., Mallard, C. “The consequences of fetal growth restriction on brain structure and neurodevelopmental outcome.” J Physiol (Lond) 594 (2016): 807–23. DOI: 10.1113/JP271402
  24. Muresan, D., Rotar, I.C., Stamatian, F. “The usefulness of fetal Doppler evaluation in early versus late-onset intrauterine growth restriction. Literature review.” Med Ultrason 18.1 (2016): 103–9. DOI: 10.11152/mu.2013.2066.181.dop
  25. Levytska, K., Higgins, M., Keating, S., et al. “Placental pathology in relation to uterine artery doppler findings in pregnancies with severe intrauterine growth restriction and abnormal umbilical artery Doppler changes.” Am J Perinatol 34.5 (2017): 451–7. DOI: 10.1055/s-0036-1592347
  26. Sibley, C.P. “Treating the dysfunctional placenta.” J Endocrinol 234.2 (2017): R81–R97. DOI: 10.1530/JOE-17-0185
  27. Spatling, L., Classen, H.-G., Kisters, K., et al. “Supplementation of Magnesium in Pregnancy.” J Preg Child Health 4 (2017): 302. DOI: 10.4172/2376-127X.1000302



How to Cite

Kravchenko, O. (2021). Algorithm for the diagnosis and treatment of primary placental dysfunction in pregnant women of risk groups. REPRODUCTIVE ENDOCRINOLOGY, (61), 33–38.



Pregnancy and childbirth